|
|
|
22.08.25 - 20:03
|
INVESTOR DEADLINE MONDAY: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT (PR Newswire)
|
|
|
SAN DIEGO, Aug. 22, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), have until this Monday, August 25, 2025 to seek......
|
|
|
|
|
|
|
|
|
22.08.25 - 19:30
|
Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance (24/7 Wall St.)
|
|
|
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug market, revolutionizing diabetes and obesity treatment with its blockbuster drugs Ozempic and Wegovy. These medications, leveraging the power of semaglutide, became household names, driving NVO to the forefront of the pharmaceutical industry. However, the market turned […]
The post Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma's Path to Dominance appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
22.08.25 - 18:39
|
Saudi Arabia Diabetes Drug Market Trends and Company Analysis Report 2025-2033 Featuring Novo Nordisk, AstraZeneca, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Novartis - ResearchAndMarkets.com (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--The "Saudi Arabia Diabetes Drug Market Trends & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering.
The Saudi Arabia Diabetes Drug Market is anticipated to grow to US$ 1.33 billion by 2033, from US$ 773.6 million in 2024, growing at a CAGR of 6.22% from 2025 to 2033
This growth is due to an increase in the prevalence of diabetes, enhanced awareness, government healthcare expenditure, and acceptance of new therapeutic agents like SGLT2 inhibitors, GLP-1 receptor agonists, and biosimilar insulins.
Diabetes medication in Saudi Arabia is experiencing growing popularity because of the prevalence of diabetes, which is largely caused by sedentary lifestyles, eating habits, and obesity. Strategic government efforts, such as Vision 2030, focus on enhanced access to healthcare and chronic disease management. The increasing number of diabetics, heightened awareness, and upgraded diagnostic facilities are driving demand for traditional as well as advanced treatmen...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
